Antonio Pinto

27PUBLICATIONS
105CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Apr 10, 2026
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma.

Gabriele Gugliotta, Lisa Argnani, Martina Cantelli

|Jan 10, 2026
Nodal Marginal Zone Lymphoma with Prominent Expansion of PD-1+ T-Follicular Helper Cells: A Persistent Diagnostic Challenge with a Heterogeneous Mutational Architecture.

Stefania Crisci, Annarosaria De Chiara, Maria Oro

|Dec 24, 2025
Health-Related Quality of Life and Symptom Burden in Patients with Diffuse Large B-Cell Lymphoma Before Treatment with Tafasitamab and Lenalidomide: An Ad Hoc Analysis of Italian Real-World Data from the PRO-MIND Study.

Pier Luigi Zinzani, Nicola Battaglia, Mario Lapecorella

|Nov 04, 2025
Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B-Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts.

Antonio Pinto, Carmelo Carlo-Stella, Monia Marchetti

|Aug 14, 2025
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Alex F Herrera, Stephen M Ansell, Pier Luigi Zinzani

|Jun 02, 2025
The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study.

Rosaria De Filippi, Fortunato Morabito, Giovanni Tripepi

Pageof 5

Frequent Collaborators

10 joint publications

Rosaria De Filippi

8 joint publications

Pierluigi Zinzani

5 joint publications

Paolo Corradini

4 joint publications

Stephane Chauvie